

12 June 2023

## **SACT (Systemic Anti-Cancer Therapy) treatments for Endometrial Cancer**

**Question One - Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?**

Yes

**Question Two - How many patients were treated for endometrial cancer in the past 6 months with the following treatments:**

**Dostarlimab:** Not used yet – in testing

**Hormone therapy (Progesterone or Letrozole):** These are drugs prescribed by GPs so the information requested is not available in RISOH (Regional Information System Oncology & Haematology) query field, therefore we are unable to provide this information.

**Pembrolizumab monotherapy:** <5

**Pembrolizumab in combination with Lenvatinib:** <5

**Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide):**

**Carboplatin only:** 26

**Carboplatin and paclitaxel:** 24

**Paclitaxel only:** <5

**Cisplatin:** <5

**Any other SACT:** <5

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.

**Question Three - How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:**

**Hormone therapy (Progesterone or Letrozole):** These are drugs prescribed by GPs so the information requested is not available in RISOH (Regional Information System Oncology & Haematology) query field, therefore we are unable to provide this information.

**Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide):**

**Carboplatin only:** 21

12 June 2023

**Carboplatin and paclitaxel: 20**

**Cisplatin: <5**

**Any other SACT: <5**

**Question Four - Of the patients treated for endometrial cancer in the past 6 months with any SACT regimen, how many patients had high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)?**

The information requested is not available in RISOH (Regional Information System Oncology & Haematology) query field.

To collate this information an extensive trawl of patient notes would be required. We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

**Question Five - Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part:**

The only available endometrial study, just closed to recruitment on 26 May 2023, was RANGO - Rare Neoplasms of Gynaecological Origin which recruited 33 patients locally.